PvDBPII/Matrix-M1

Biologic

UUniversity of Oxford

PvDBPII/Matrix-M1 is one of 9 biologic programs targeting Plasmodium vivax malaria. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Vivax MalariaActive, not recruiting

Plasmodium Vivax MalariaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Plasmodium Vivax Malaria

#DrugCompanyPhaseTrials

Aralen

Sanofi

Approved

4 2

Artesunate

AAmivas Inc.

Approved

1 3

Primaquine

Sanofi

Phase 3

2 4

Krintafel

GGlaxo Dba Glaxosmithkline

Phase 3

1 5

Artesunate-Amodiaquine

Sanofi

Phase 3

1 6

Pyronaridine-Artesunate

Medicines for Malaria Venture

Phase 3

1 7

Eurartesim

Ssigma-tau i.f.r. S.p.A.

Phase 2

1 8

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 1

—9

PvDBPII/Matrix-M1

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plasmodium vivax malaria1 trial

Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

Completed·UUniversity of Oxford·Phase 1/2·NCT04201431·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PvDBPII/Matrix-M1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PvDBPII/Matrix-M1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PvDBPII/Matrix-M1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oxford company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: UUniversity of Oxford

PvDBPII/Matrix-M1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plasmodium vivax malaria1 trial

References

Drug Info

Quick Facts

Related News